曲美他嗪对老年缺血性心肌病心力衰竭患者预后的影响

Effect of Rimetazidine on the Prognosis of Aged Patients with Heart Failure due to Ischemic Cardiomyopathy

目的观察曲美他嗪对老年缺血性心肌病心力衰竭患者预后的影响.方法慢性充血性心力衰竭患者80例,男62例,女18例,平均年龄(70.3±6.8)岁,随机分为对照组和治疗组,对照组给予常规药物治疗.治疗组在常规治疗基础上给予曲美他嗪治疗.采用超声分别于治疗前、治疗后3月、6月、1a、2a测定两组的左室射血分数,随访2a内两组再住院例次及心血管死亡例数.结果两组患者治疗后心功能均有不同程度的改善,但治疗组更为显著(P<0.05);两组治疗后的射血分数、再住院例次较治疗前均有明显改善,且有统计学意义(P<0.05).治疗组治疗后上述指标均优于对照组,且有统计学意义(P<0.05);心血管死亡百分率治疗组与对照组相比,差异无统计学意义.结论曲美他嗪具有改善老年缺血性心肌病心力衰竭患者预后的作用.

Objective To observe the effect of rimetazidine on the prognosis of aged patients with heart failure due to ischemic cardiomyopathy. Methods Total 80 patients with chronic congestive heart failure （62 males and 18 females） , averagely at （70.3 ± 6.8） years of age, were selected from those who were hospitalized in the Department of Geriatrics, the Third People＇s Hospital of Yunnan Province. All selected patients were randomly devided into control group and treatment group. Regular drug therapy was given to patients in control group, rimetazidine was applied to patients in treatment group besides regular drug therapy. Left ventricular ejection was measured with ultrasound in both groups before treatment and 3 months, 6 months, 1 year and 2years after treatment, and the number of rehospitalized cases and cardiovascular death cases within the 2-year follow - up was investigated. Results The cardiac function of patients was improved after treatment in both groups, and the cardiac function of patients in treatment group was better than those in control group （P 〈 0.05 ）. Left ventricular ejection of patients and the number of rehospitalized cases was improved after treatment in both groups （P 〈 0.05 ）. The therapeutic effects in treatment group was better than control group （P 〈 0.05）. There was no obvious difference in the number of cardiovascular death cases between control group and treatment group.Conclusion Rimetazidine can improve the prognosis of aged patients with heart failure due to ischemic cardiomyopathy.